Shorts
1:00
New Oral Treatments to Revolutionize Psoriasis Care
9 months ago
by
Ronald Vender, MD, FRCPC
0:53
From Consultation to Transformation: Emphasizing Strategic Aesthetics at PDPA 2025
10 months ago
by
Kachiu C. Lee, M.D.
0:42
Supporting Skin Health in the Prejuvenation Era
10 months ago
by
Amy B. Lewis, MD
0:30
What Makes APG777 a Potential First-line Therapy?
10 months ago
by
Emma Guttman-Yassky, MD, PhD
0:59
Treating Dermatological Diseases As Processes
10 months ago
by
Brian Kim, MD
0:31
Fighting Misinformation on Injectables and HA Fillers
10 months ago
by
Lisa Espinoza, MD
0:59
How Dermatologists Can Best Support Patients With BFRBs
10 months ago
by
Sofia Wenzler, PhD
1:27
What's the Future of Dosing With ORKA-001?
10 months ago
by
Andrew Blauvelt, MD, MBA
1:30
Bridging the Gap Between Patients and Clinical Trials
a year ago
by
Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS
0:56
Reviewing Ruxolitinib's Expanded Indication for Pediatric Patients With AD
a year ago
by
Nicole Harter, MD
0:42
Addressing Health Care Bias in Treating Patients of Color
a year ago
by
Buchi Neita, MCMSc, PA-C
0:55
How Deuruxolitinib Blocks Autoimmune Hair Loss in Alopecia Areata
a year ago
by
Vimal Prajapati, MD, FRCPC, DABD
1:30
Essential Recommendations for Dermatologists
a year ago
by
Nayan Patel, PharmD
1:30
Skin Care Trends: Facts vs Misinformation
a year ago
by
Anthony M. Rossi, MD, FAAD, FACMS
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5